Evidence map›Paper›PMID 33655410›Full record

ArticleInfectious diseases and therapy2021

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.

Massimo Andreoni, Giovanni Di Perri, Marcello Persico, Andrea Marcellusi, Olivier Ethgen, Yuri Sanchez Gonzalez, Mark Bondin, Zhenzhen Zhang, Antonella De Michina, Rocco Cosimo Damiano Merolla and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Massimo AndreoniUniversity of Tor Vergata, Rome, Italy. andreoni@uniroma2.it.
Giovanni Di PerriDepartment of Clinical Infectious Diseases, University of Turin, Turin, Italy.
Marcello PersicoInternal Medicine and Hepatology Unit, Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
Andrea MarcellusiCenter for Economic and International Studies, Faculty of Economics, University of Tor Vergata, Rome, Italy.
Olivier EthgenSERFAN Innovation, Namur, Belgium.
Yuri Sanchez GonzalezAbbVie Inc, North Chicago, IL, USA.
Mark BondinAbbVie Inc, North Chicago, IL, USA.
Zhenzhen ZhangAbbVie Inc, North Chicago, IL, USA.
Antonella De MichinaAbbVie S.R.L, Rome, Italy.
Rocco Cosimo Damiano MerollaAbbVie S.R.L, Rome, Italy.
Antonio CraxìGI and Liver Unit, PROMISE, University of Palermo, Palermo, Italy.
AbbVie (United States) · USABB (Italy) · ITUniversity of Rome Tor Vergata · ITUniversity of Liège · BEUniversity of Palermo · ITUniversity of Salerno · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy.

methodsA multicohort Markov model was used to assess the collective number of healthcare visits and time on treatment with 8-week vs 12-week G/P in the HCV-infected population of Italy from 2019 to 2030, using healthcare resource data from post-marketing observational studies of G/P. Increased treatment capacity and downstream clinical and economic benefits were also assessed assuming the reallocation of saved healthcare visits to treat more patients.

resultsModeled outcomes showed that by 2030, 8-week treatment saved 27,006 years on therapy compared with 12-week treatment, with 21,065 fewer hepatologist visits. Reallocating these resources to treat more patients could increase capacity to treat 5064 (1.4%) more patients with 8 weeks of G/P, all with CC. This increased treatment capacity would further avoid 2257 cases of end-stage liver disease, 893 liver-related deaths, and provide net savings to the healthcare system of nearly €70 million.

conclusionThe modeled comparisons between 8- and 12-week treatment with G/P show that shorter treatment duration can lead to greater time and resource savings, both in terms of healthcare visits and downstream costs. These benefits have the potential to enable the treatment of more patients to overcome elimination barriers in Italy through programs aimed to engage and treat targeted HCV populations.

Indexed as

EliminationGlecaprevir/pibrentasvirHepatitis C virusItalyTreatment duration

Identifiers

PMID33655410
PMCPMC7925258
OpenAlexW3134195964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.